Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Assouline B, Kahn R, Hodali L, Condiotti R, Engel Y, Elyada E, Mordechai-Heyn T, Pitarresi JR, Atias D, Steinberg E, Bidany-Mizrahi T, Forkosh E, Katz LH, Benny O, Golan T, Hofree M, Stewart SA, Atlan KA, Zamir G, Stanger BZ, Berger M, Ben-Porath I. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Nat Commun. 2024 Jul 22; 15(1):6162.
-
Patel SA. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia. Br J Haematol. 2024 Apr; 204(4):1137-1138.
-
Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.
-
Degtjarik O, Golovenko D, Diskin-Posner Y, Abrahms?n L, Rozenberg H, Shakked Z. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat Commun. 2021 12 03; 12(1):7057.
-
Azizi A, Ediriwickrema A, Dutta R, Patel SA, Shomali W, Medeiros B, Iberri D, Gotlib J, Mannis G, Greenberg P, Majeti R, Zhang T. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020 11; 61(11):2700-2707.
-
Giampetruzzi A, Danielson EW, Gumina V, Jeon M, Boopathy S, Brown RH, Ratti A, Landers JE, Fallini C. Modulation of actin polymerization affects nucleocytoplasmic transport in multiple forms of amyotrophic lateral sclerosis. Nat Commun. 2019 08 23; 10(1):3827.
-
Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
-
Yang Y, Kelly P, Shaffer AL, Schmitz R, Yoo HM, Liu X, Huang DW, Webster D, Young RM, Nakagawa M, Ceribelli M, Wright GW, Yang Y, Zhao H, Yu X, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Staudt LM. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. Cancer Cell. 2016 Apr 11; 29(4):494-507.
-
Moser T, Celma C, Lebert A, Charrault E, Brooke R, Murphy PJ, Browne G, Young R, Higgs T, Evans D. Hydrophilic Organic Electrodes on Flexible Hydrogels. ACS Appl Mater Interfaces. 2016 Jan 13; 8(1):974-82.
-
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87.